Stockreport

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

EyePoint, Inc.  (EYPT) 
Last eyepoint, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF – DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials antic [Read more]